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Abstract: Neorogioltriol is a tricyclic brominated diterpenoid isolated from the organic 
extract of the red algae Laurencia glandulifera. In the present study, the anti-inflammatory 
effects of neorogioltriol were evaluated both in vivo using carrageenan-induced paw edema 
and in vitro on lipopolysaccharide (LPS)-treated Raw264.7 macrophages. The in vivo study 
demonstrated that the administration of 1 mg/kg of neorogioltriol resulted in the significant 
reduction of carregeenan-induced rat edema. In vitro, our results show that neorogioltriol 
treatment decreased the luciferase activity in LPS-stimulated Raw264.7 cells, stably 
transfected with the NF-κB-dependent luciferase reporter. This effect on NF-κB activation 
is not mediated through MAPK pathways. The inhibition of NF-κB activity correlates  
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with decreased levels of LPS-induced tumor necrosis factor-alpha (TNFα) present in 
neorogioltriol treated supernatant cell culture. Further analyses indicated that this product 
also significantly inhibited the release of nitric oxide and the expression of 
cyclooxygenase-2 (COX-2) in LPS-stimulated Raw264.7 cells. These latter effects could 
only be observed for neorogioltriol concentrations below 62.5 µM. To our knowledge, this 
is the first report describing a molecule derived from Laurencia glandulifera with  
anti-inflammatory activity both in vivo and in vitro. The effect demonstrated in vitro may 
be explained by the inhibition of the LPS-induced NF-κB activation and TNFα production. 
NO release and COX-2 expression may reinforce this effect.  
Keywords: anti-inflammatory; neorogioltriol; Laurencia; TNFα; NF-κB; NO;  
COX-2; carrageenan 
 
1. Introduction 
Natural products derived from plants provide an interesting and promising source for isolating and 
developing therapeutic molecules to fight against various diseases, including inflammatory ones [1]. In 
this respect, different natural products derived from marine organisms have been reported to exhibit a 
broad spectrum of pharmacological activity, including anti-inflammatory effects [2,3]. 
During the process of inflammation, different cell types are recruited, including monocytes that 
differentiate locally into macrophages. This leads to the regulated production of various pro- and  
anti-inflammatory mediators including cytokines, such as TNFα, chemokines and inducible enzymes 
(COX-2 and iNOS) that play critical roles in controlling the inflammatory processes. The expression of 
most of these proteins is controlled, at least in part, through the activation of a conserved and 
ubiquitous transcription factor, NF-κB which plays a key role in inflammatory response. 
Several natural products with anti-inflammatory effects have been shown to target and modulate the 
NF-κB signaling pathway, including a number of terpenoids [4,5]. Molecules belonging to this family 
were isolated from different marine organisms including coral, sponge and algae [3]. Algae, 
particularly red algae, represent a rich source of different secondary metabolites, the majority of which 
consists of acetogenins, halogenated diterpenes and sesquiterpenes [6–8]. Several molecules were 
derived from the genus Laurencia and have been shown to exhibit a number of different  
activities [9–11]. Using total extracts obtained from different algae, numerous studies have shown 
associated anti-inflammatory effects both in vivo [12,13] and in vitro [14,15]. However, to the best of 
our knowledge, purified molecules with anti-inflammatory effects have not yet been documented from 
the genus Laurencia. 
Recently, we have isolated neorogioltriol, a new diterpene with analgesic activity [16] from the 
organic extract of the red algae Laurencia glandulifera. In this report we investigated the  
anti-inflammatory activity of this molecule both in vivo, experimenting on carrageenan-induced 
inflammation in the rat paw and in vitro, based on the expression of NF-κB and COX-2, as well as the 
release of TNFα and NO, from LPS-stimulated Raw264.7 macrophages. 
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2. Results and Discussion 
2.1. Effect of Neorogioltriol on Carrageenan-Induced Paw Edema in Rats 
The carrageenan-induced paw edema model in rats, one of the well-established acute inflammatory 
models in vivo, was used to test the anti-inflammatory activity of neorogioltriol. In the control group, 
the intraplantar injection of 100 µL of carrageenan (0.6%) into the rat’s hind paw induced a significant 
increase in paw edema (Table 1). This observation indicates the development of an inflammatory 
response and paw swelling (edema). The edema was present as early as one hour after carrageenan 
injection, progressed rapidly and persisted for at least 5 h after treatment. Both dexamethasone and 
ASA, used as positives controls, inhibited the oedematogenic response evoked by carrageenan in rats 
at all assessment times. However, as previously reported [17], the kinetics of the effect of both 
components was different: whereas the dexamethasone-associated effect was rapid and produced a 
42% reduction of the edema after the first hour, the ASA-induced effect was slower (only 17% in the 
first hour), but reached a 59% inhibition by the fifth hour. Treatment of rats with the neorogioltriol 
molecule at an intraperitoneal dose of 1 mg/kg significantly reduced paw swelling at all time points 
tested (Table 1). This reduction was about 28% after the first hour and reached a maximum of 58% at 
3 h post injection. Moreover, a 1 mg/kg dose of neorogioltriol proved as effective as 300 mg/kg of 
ASA in reducing inflammation. 
Using the carrageenan-induced paw edema model in rats, our results showed that the red  
algae-derived natural molecule neorogioltriol was able to reduce the formation of edema in a 
concentration- and time-dependent manner.  
Table 1. Effect of neorogioltriol on carrageenan-induced paw edema in rats. 
Times after carageenan injection (h) 1 h 3 h 5 h 
Groups Treatment n 
Dose 
(mg/kg) 
EV EI EV EI EV EI 
(10
−2
 mL) (%) (10
−2
 mL) (%) (10
−2
 mL) (%) 
Control Control 6 - 18.3 ± 2.7 - 56.3 ± 5.8 - 69 ± 7.7 - 
Tests Neorogioltriol 
6 0.5 15.5 ± 3.1 15.3 42 ± 5.5 (*) 33.3 49.1 ± 6.1 28.8 
1 14.1 ± 3 (*) 22.95 23.5 ± 3.7 (***) 58 33 ± 3.5 (**) 52.27 
References 
Aspirin (ASA) 6 300 16.5 ± 3.1 9.83 25.1 ± 6.7 (**) 55.17 28.1 ± 2.2 (**) 59.27 
Dexamethasone 6 1 9.83 ± 1.8 47.54 39.3 ± 3.8 (***) 42.5 32.5 ± 5.7 (***) 52.86 
Neorogioltriol (0.5 or 1 mg/kg) was administrated one hour before the intraplantar carrageenan injection. 
Reference animals were treated with dexamethasone (1 mg/kg) or aspirin (ASA) (300 mg/kg); control 
animals received vehicle (0.9% NaCl) used to re-suspend the different drugs. Six animals were used for each 
treatment group. The drugs were administrated by intraperitoneal injection. The edema volume (EV) was 
determined immediately before and 1, 3, and 5 h after the carrageenan injection. When needed, the edema 
inhibition (EI) was calculated. The percentage of inhibition in treated rats versus control was calculated using 
the following formula: EI (%) = ([(Ct − C0) control − (Ct − C0) treated]/(Ct − C0) control) × 100 where  
Ct correspond to edema volume after carrageenan injection and C0 correspond to edema volume before 
carrageenan injection. The values are expressed as the mean ± SD; * p < 0.05; ** p < 0.01; *** p < 0.001 
determined by Student’s t test compared with control. 
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2.2. Cell Viability 
Cytotoxic potential of neorogioltriol on Raw264.7 cells was tested using the MTT assay. Our result 
shows that in the presence of up to 250 µM of neorogioltriol, Raw264.7 macrophages viability was not 
significantly lower than in non-treated cells. We find cytotoxicity only at the highest neorogioltriol 
concentration (500 µM) which causes an optical density (OD) reduction of about 50%. 
Figure 1. Raw264.7 macrophages were either left untreated or were treated with various 
concentrations of neorogioltriol. The cytotoxic effects were recorded at an observation 
period of 24 h by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) test as described under “Experimental Section”. The cell number in each well was 
recorded in the form of optical density (OD). Data are expressed as means ± SD of three 
independent experiments performed in triplicates. Results were analyzed by using one-way 
analysis of variance (ANOVA) with significance of p < 0.05. 
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2.3. Effect of Neorogioltriol on TNFα Release, NO Production and COX-2 Expression in  
LPS-Stimulated Raw264.7 Cells 
Carrageenan-induced rat paw edema has been fully characterized and shown to be associated with 
the production of several inflammatory mediators [18,19] including TNFα, prostaglandins and nitric 
oxide release [20–22]. 
We first analyzed the effects of neorogioltriol in vitro, on different inflammatory molecules starting 
with TNFα. The release of TNFα was measured using ELISA assay in the supernatant of  
LPS-stimulated Raw264.7 cells, pre-treated or not with neorogioltriol for 30 min. The treatment of 
resting Raw264.7 cells with LPS increased the production of TNFα. For all the concentrations tested, 
neorogioltriol significantly inhibited TNFα production (Figure 2). 
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Figure 2. Effects of neorogioltriol on lipopolysaccharide (LPS)-induced tumor necrosis 
factor-alpha (TNFα) production in Raw264.7 cells. Cells were treated with different 
concentrations ranging from 0.125 µM to 62.5 μM of neorogioltriol for 30 min prior to 
LPS (100 ng/mL) stimulation. Supernatants were collected 24 h later and cytokine content 
was measured by ELISA. Results are expressed as mean values of three independent 
experiments performed in duplicates, ±standard deviation. Statistically significant differences 
(p < 0.003) between all groups are verified by the Kruskal-Wallis non-parametric test. 
 
Cyclooxygenase-2 (COX-2) is the key enzyme regulating the production of prostaglandins, the 
central mediators of inflammation. On the other hand, iNOS activation induces massive NO production 
at the site of inflammation. We thus investigated the effect of our molecule on LPS-induced COX-2 
expression by Western blot and on NO production by measuring the released nitrite in the culture 
medium by Griess reaction. 
Our results show that in murine Raw264.7 cells, LPS treatment (100 ng/mL for 24 h) induces the 
expression of COX-2 (Figure 3A) and increases NO production 30-fold, as compared to controls. After 
neorogioltriol pretreatment, the LPS-induced nitrite release was inhibited. At concentrations ranging 
from 0.125 µM to 12.5 µM, neorogioltriol significantly reduced the level of NO production. However, 
for neorogioltriol concentrations above 25 µM the curve of NO release turns upward and at 62.5 µM 
(25 µg/mL) of neorogioltriol, NO release is almost similar to untreated cells (Figure 3A). 
The expression of COX-2 was also tested in cells treated with 12.5 µM, 25 µM and 62.5 µM 
neorogioltriol prior to LPS stimulation. Consistent with the inhibitory effect on NO release, the results 
(Figure 3B) show that neorogioltriol up to 25 µM inhibited the LPS induced COX-2 expression. 
However, at 62.5 µM the COX-2 expression is partially restored. 
Taken together, our data show that, whereas neorogioltriol has no effect by itself (data not shown), 
this molecule inhibits the expression of TNFα and COX-2 and the production of NO induced by  
LPS stimulated Raw264.7 cells. Neorogioltriol however, shows a biphasic effect since this molecule 
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fails to inhibit the expression of key inflammatory mediators, such as COX-2 and NO at the  
highest concentrations. 
Figure 3. (A) The effects of neorogioltriol on LPS-induced nitric oxide (NO) released in 
Raw264.7 cells. Cells were treated with different concentrations ranging from 0.125 µM to 
62.5 μM of neorogioltriol for 30 min and then LPS (100 ng/mL) was added. Supernatants 
were collected 24 h later and NO content was measured by ELISA. Results were mean 
values of three independent experiments, performed in duplicates, ±standard deviation. 
Statistically significant differences (p < 0.038) between all groups are verified by the 
Kruskal-Wallis non-parametric test; (B) The effects of neorogioltriol on LPS-induced 
COX-2 expressions in Raw264.7 cells. Cells were treated with different concentrations 
(12.5 µM, 25 µM and 62.5 μM) of neorogioltriol for 30 min; then, LPS (100 ng/mL) was 
added and the cells were incubated for 24 h. Total cellular proteins were resolved by  
SDS-PAGE, transferred to nitrocellulose membranes, and detected with specific 
antibodies, as described in the Experimental Section. A representative immunoblot of three 
separate experiments is shown.  
(A) 
 
(B) 
NS                0             12. 5             25             62.5       Neorogiotriol (µM)
+                +                +              +            LPS (100 ng/ml) (24h)
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ERK1/2- T
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2.4. Effects of Neorogioltriol on NF-κB Transactivation in LPS-Stimulated Raw264.7 Cells 
The anti-inflammatory potential of terpenes has been linked to their capacity to suppress NF-κB 
signaling [4,23] which coordinates the expression of proinflammatory enzymes and cytokines 
including iNOS, COX-2 and TNFα [24–26]. Neorogioltriol was thus evaluated in vitro for its ability to 
inhibit LPS-mediated NF-κB transcriptional activity. Raw264.7 cells, stably transfected with  
pNF-κB-luc plasmid, containing three NF-κB target sequences linked upstream to the luciferase 
reporter gene, were either stimulated with LPS or treated with different concentrations of 
neorogioltriol prior to LPS stimulation. Our result shows that LPS induces NF-κB activation. The  
pre-treatment with neorogioltriol prior to LPS stimulation significantly decreased LPS induced NF-κB 
transactivation (Figure 4). This result shows that the anti-oedematogenic effect of neorogioltriol 
correlates with the suppression of NF-κB activation. 
However, despite reducing NF-κB activity, high concentrations of neorogioltriol fail to inhibit the 
expression of certain NF-κB-dependent genes that are relevant to the inflammatory process, such as 
COX-2. These results suggest that the observed loss of anti-inflammatory efficacy at high doses of 
neorogioltriol was independent of NF-κB or indirectly dependent on NF-κB inhibition.  
Figure 4. The inhibition of NF-κB activation by neorogioltriol. Cells were stably 
transfected with a pNF-κB-Luc reporter and then were pretreated for 30 min with different 
concentrations (12.5 µM, 25 µM and 62.5 μM) of neorogioltriol. LPS (100 ng/mL) was 
then added and the cells were further incubated for 6 hours. The cells were harvested and 
luciferase activities were determined in cell lysates and normalized to protein content using 
a luminometer TD-20/20 (Promega, charbonnieres, France). Results are representative of 
three different experiments and are expressed as the fold increase in luciferase activity 
induced by the specific experimental condition, relative to the luciferase activity measured 
in LPS stimulated cells. Statistically significant differences (p < 0.01) between all groups 
are verified by the Kruskal-Wallis non-parametric test.  
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2.5. Effect of Neorogioltriol on MAPK in LPS-Stimulated Raw264.7 Cells 
The mitogen-activated protein (MAP) kinases play a key role in the regulation of cellular response 
to cytokines and stresses and are also known to be important for NF-κB activation. We thus tested 
whether the observed loss of anti-inflammatory efficacy may be mediated through MAPK activation. 
We first studied the effect of neorogioltriol on LPS-induced MAPK activation. Our results show 
that at the highest concentrations used (25 µM and 62.5 µM), the neorogioltriol molecule fails to 
interfere with LPS-dependent ERK activation and only slightly inhibited the p38 MAPK 
phosphorylation (Figure 5). Moreover, the inhibition of MAPK pathways by PD98059 or SB203580 
treatment did not alter the capacity of neorogioltriol to inhibit the LPS-induced NF-κB transactivation 
(data not shown). 
Figure 5. Effect of neorogioltriol on MAPK activation in LPS-stimulated Raw264.7 cells. 
Cells were pretreated for 30 min with 62.5 μM (or 25 μM) of neorogioltriol. LPS  
(100 ng/mL) was then added and the cells were further incubated for indicated times. Cells 
were collected and subjected to Western blotting with antibodies specific for phosphorylated 
forms of p38 (p38MAPK-P) or ERK1/2 (ERK1/2-P). Total ERK immunoblots were shown 
as loading control; similar results were obtained for the two concentrations of neorogioltriol 
used. Results are representative of two independent experiments. 
 
MAPKs have been reported to be involved in the LPS-induced iNOS expression signaling  
pathway [27] which regulates the production of NO which, in turn, may enhance the expression of 
COX-2. On the other hand, at the highest concentrations used, neorogioltriol does not display a 
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significant inhibitory effect on MAPK phosphorylation. Using SB203580 (or PD98059), we thus tried 
to see whether or not MAPK activity may explain the recovery of NO release by the cells treated with 
the highest concentrations of neorogioltriol. 
Raw264.7 cells were incubated for one hour with SB203580 (or PD98059) prior to neorogioltriol 
treatment and LPS stimulation. Our results show that the use of p38MAPK (or ERK1/2) inhibitor does 
not inhibit the recovery of NO production observed with the highest concentration of neorogioltriol 
(Figure 6) suggesting that abrogation of NO inhibition in the neorogioltriol treated cells is not 
dependent on MAPK activation. 
Figure 6. Effect of p38 MAPK inhibitor on NO release in neorogioltriol treated Raw264.7 
cells. Cells were pretreated for one hour with SB203580 (10 μM) and then with 
neorogioltriol (12.5 μM, 25 μM or 62.5 μM) before LPS stimulation. Supernatants were 
collected 24 h later and NO content measured by Griess reagent. Results were mean values 
of two independent experiments, performed in duplicate, ±standard deviation. Comparisons 
between SB203580 treated and non treated cells were made using the non-parametric 
Mann-Whitney test, with significance of p < 0.05. 
 
Taken together, these results show that the effect of neorogioltriol at high concentration is 
independent of MAPK and NF-κB. This effect may however be indirectly dependent on NF-κB 
inhibition. Indeed, some non steroid anti-inflammatory drugs (NSAIDs) are known to activate COX-2 
through signaling pathways independent of NF-κB and MAPK and involving the nuclear factor 
PPARγ. On the other hand, LPS has been shown to drive down PPARγ expression through the 
activation of NF-κB [28]. This may suggest that the repression of NF-κB by neorogioltriol inhibits the 
negative loop of NF-κB on PPARγ, which may allow the latter to induce the expression of NOS2 and 
COX-2. We are currently investigating this hypothesis. 
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3. Experimental Section 
3.1. Isolation of Neorogioltriol 
The collection of Laurencia glandulifera and the extraction and isolation procedure of 
neorogioltriol have been already described [16]. 
3.2. Carrageenan-Induced Paw Edema 
The anti inflammatory activity on carrageenan-induced paw edema was determined according to the 
method described by [29]. Naïve rats were randomly allocated to four groups and pretreated 1 hour 
before intraplantar administration of 100 μL of 0.6% of carrageenan. (i) Control group: received  
2.5 mL/kg of vehicle (physiological solution (0.9% NaCl)) used to re-suspend the different drugs  
(ii) Standard group 1: received 1 mg/kg of dexamethasone (2.5 mL/kg); (iii) Standard group 2: 
received 300 mg/kg of asprin (2.5 mL/kg); and (iiii) Test group: received 1 mg/kg or 0.5 mg/kg of 
neorogioltriol (2.5 mL/kg). The drugs were administrated by intraperitoneal injection. The edema 
volume was determined using a plethysmometer (model 7150, Ugo Basile, Italy) prior to and 1, 3 and 
5 h after carrageenan injection. The percentage of inhibition in treated rats versus control was 
calculated using the following formula: EI (%) = ([(Ct − C0) control − (Ct − C0) treated]/(Ct − C0) 
control) × 100 where Ct correspond to edema volume after carrageenan injection and C0 correspond to 
edema volume before carrageenan injection. 
3.3. Reagents and Antibodies 
ERK1/2 antibodies and p38 MAPK antibodies were from Ozyme (Ozyme, Saint Quentin en 
Yveline, France). COX-2 antibody was from Becton Dickinson (BD Biosciences, France). PD098059, 
SB203580, LPS and griess reagent were purchased from Sigma (Sigma-Aldrich, Taufkirchen, Germany). 
3.4. Cells Culture 
The mouse macrophagic cell line Raw264.7 cells were obtained from American Type Culture 
Collection and were grown at 37 °C, in RPMI 1640, supplemented with 5 mM L-glutamine, 10% heat 
inactivated fetal calf serum (endotoxin-free; HyClone), penicillin (100 U/mL) and streptomycin  
(100 µg/mL). 
3.5. Cytotoxicity Test 
The MTT assay was used to test the potential toxic effects of neorogioltriol on the mouse 
macrophagic cell line Raw264.7 cells. Briefly, Raw264.7 cells were incubated with various 
concentrations of neorogioltriol for 24 h. MTT solution was added to cell cultures at the final 
concentration of 0.5 mg/mL and cells were incubated for an additional 2 h. Thereafter, medium was 
removed and plates were thoroughly washed with PBS. Cells were finally lysed in DMSO. The 
absorbance of each well at 540 nm was read by an automatic microplate reader. The average OD 
measured at different concentrations of neorogioltriol was compared using one-way analysis of 
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variance (ANOVA). Proliferation of the cells exposed to the drugs was compared to the negative 
control. P < 0.05 was considered statistically significant. 
3.6. Transfection and Luciferase Assay 
Raw264.7 cells were stably transfected by electroporation with an NF-κB luciferase reporter 
construct containing three NF-κB target sequences in tandem fused to the luciferase reporter gene  
(3X-NF-κB-Luc), a gift from Dr J. Pierre (Faculté de pharmacy, Chatenay-Malabry, France). Cells 
were either left untreated or were treated with neorogioltriol at different doses for 30 min, they were 
then washed and stimulated with LPS (100 ng/mL) for an additional 6 hours. Protein concentration 
was determined by microBCA assay. Luciferase activity was determined using a luminometer TD-20/20 
(Promega, charbonnieres, France). 
3.7. Western Blot Analysis 
Cell extracts were obtained by adding 25 µL of lysis buffer containing 10 mM Tris-HCL, pH 7.5, 
50 mM NaCl, 50 mM sodium fluoride (NaF), 2 mM EDTA, 1 mM ethylene glycol-bis  
(β-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 2% Nonidet-P40 (NP-40), 0.75% sodium 
deoxycholate (DOC), 1 mM orthovanadate, 1 µg/mL aprotinine, 1 mM PMSF, 1 mM DTT. After  
30 min incubation on ice, the extracts were centrifuged at 15,000 rpm for 20 min. 25 µg of whole cell 
lysates were resolved by electrophoresis in a 12% SDS-polyacrylamide gel. Resolved proteins were 
electrophoretically transferred onto PVDF sheets (Hybond-P; Amersham) and membranes were 
blocked by incubation in 3% non-fat milk and 0.1% Tween in PBS for 1 h at room temperature 
followed by incubation with COX-2 antibody in 0.1% Tween-PBS. Bound antibody was detected by 
incubation with horseradish peroxidase-coupled secondary antibody (Amersham Pharmacia Biotech., 
Buckinghamshire, UK). To ensure equal loading, the blots were then stripped (62.5 mM Tris, pH 6.8), 
0.1 M β-mercaptoethanol, 2% SDS) and re-probed with ERK1/2 antibody. 
3.8. Measurements of Nitrite Production and Cytokine Assays 
Macrophage cells were seeded in 24 wells, treated with different concentrations of neorogioltriol or 
vehicle for 30 min and then incubated with 100 ng/mL of LPS for 24 h. NO production in culture 
supernatant was spectrophotometrically evaluated by measuring nitrite, an oxidative product of NO. 
Nitrites were measured by Griess reaction by mixing 50 µL of culture supernatant with 50 µL of  
griess reagent. Absorbance was measured in microplates at 540 nm against a calibration curve  
with sodium nitrite standard. Supernatants were also analysed for TNFα content using BD  
Pharmingen (BD Biosciences, France) antibodies. The assays were performed according to the  
manufacturer’s instructions. 
3.9. Statistical Analysis 
For TNFα production, NO release and NF-κB activation, the Kruskal-Wallis test was used to 
analyze significant differences between groups. The comparison between the two groups (presence or 
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absence of SB203580) was performed using the Mann-Whitney test. For all statistical comparisons a  
p value <0.05 was defined as significant. 
4. Conclusions 
As far as could be ascertained, this is the first report that shows anti-inflammatory activity for a 
purified algal metabolite. We have demonstrated that, in addition to its analgesic activity [16], 
neorogioltriol exhibits anti-inflammatory activity in vivo. This effect may be explained by the capacity 
of neorogioltriol, at all concentrations tested, to inhibit NF-κB transactivation and TNFα release. The 
inhibitory effect of this compound on COX-2 expression and NO release is likely to reinforce the  
anti-inflammatory effect of neorogioltriol at concentrations below 62.5 µM. However, the exact 
mechanism of neorogioltriol action needs to be clarified and the target molecule in the cell identified.  
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